Kineta (Kineta) Effective Interest Rate on Debt % : 13.91% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Kineta Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Kineta's annualized positive value of Interest Expense for the quarter that ended in Mar. 2024 was $0.17 Mil. Kineta's average total debt for the quarter that ended in Mar. 2024 was $1.21 Mil. Therefore, Kineta's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 was 13.91%.

Kineta Effective Interest Rate on Debt % Historical Data

The historical data trend for Kineta's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kineta Effective Interest Rate on Debt % Chart

Kineta Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Effective Interest Rate on Debt %

20.16

5.59

31.21

18.84

Kineta Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Effective Interest Rate on Debt %	Get a 7-Day Free Trial							4.26	4.30	4.84	73.94	13.91

Competitive Comparison of Kineta's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Kineta's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kineta's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kineta's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Kineta's Effective Interest Rate on Debt % falls into.

Kineta Effective Interest Rate on Debt % Calculation

Kineta's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Dec. 2022 )	+	Total Debt (A: Dec. 2023 ))	/ count )
=	-1 * -0.337	/	( (2.261	+	1.317)	/ 2 )
=	-1 * -0.337	/	1.789
=	18.84 %

where

	Total Debt (A: Dec. 2022 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	1.378	+	0.883
=	2.261

	Total Debt (A: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0.15	+	1.167
=	1.317

Kineta's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: Dec. 2023 )	+	Total Debt (Q: Mar. 2024 ))	/ count )
=	-1 * -0.168	/	( (1.317	+	1.098)	/ 2 )
=	-1 * -0.168	/	1.2075
=	13.91 %

where

	Total Debt (Q: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0.15	+	1.167
=	1.317

	Total Debt (Q: Mar. 2024 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0.15	+	0.948
=	1.098

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

Kineta (NAS:KA) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Kineta Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Kineta's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kineta (Kineta) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kineta Inc (NAS:KA) » Definitions » Effective Interest Rate on Debt %

Comparable Companies

Traded in Other Exchanges

J75:Germany

Address

219 Terry Avenue North, Suite 300, Seattle, WA, USA, 98109

Website

https://www.kinetabio.com

Kineta Inc is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. The company's asset is KVA12.1, a VISTA blocking immunotherapy.

Executives

Raymond J. Bartoszek	director	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Shawn Iadonato	director, officer: Chief Executive Officer	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Craig W. Philips	officer: President	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Pauline Kenny	officer: General Counsel	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Keith Baker	officer: Chief Financial Officer	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Thierry Guillaudeux	officer: Chief Scientific Officer	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Scott J. Dylla	director	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Marion R Foote	director	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Michael D Wyzga	officer: See Remarks	C/O YUMANITY, INC., 40 GUEST STREET, SUITE 4410, BOSTON MA 02135
Devin Whittemore Smith	officer: SVP and General Counsel	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Kimberlee C Drapkin	director	PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ajay Verma	officer: EVP, Head of R&D	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Lynne Zydowsky	director	C/O YUMANITY THERAPEUTICS, INC., 40 GUEST STREET, BOSTON MA 02135
Susan L. Lindquist Exempt Marital Trust	10 percent owner	C/O NANCY E. DEMPZE, HEMENWAY & BARNES, LLP, 75 STATE STREET, BOSTON MA 02109
Susan L. Lindquist Massachusetts Non-exempt Marital Trust	10 percent owner	C/O NANCY DEMPZE, HEMENWAY & BARNES, LLP, 75 STATE STREET, BOSTON MA 02109